nach oben

Erschienen in:

01.04.2023 | News item

Developmental disabilities after in utero exposure to topiramate

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Topiramate is known to cause congenital abnormalities when administered to pregnant women but it is also associated with an increased risk of neurodevelopmental disorders, advises the Malaysian National Pharmaceutical Regulatory Authority (NPRA). Its use during pregnancy should be considered only if the potential benefits outweigh the potential risks. …

Topiramate: Neurodevelopmental Disorders in Children Exposed to Topiramate During Pregnancy Internet Document : 17 Mar 2023. Available from: URL: https://npra.gov.my/index.php/en/component/content/article/449-english/safety-alerts-main/safety-alerts-2023/1527474-topiramate-neurodevelopmental-disorders-in-children-exposed-to-topiramate-during-pregnancy.html?Itemid=1391

Titel: Developmental disabilities after in utero exposure to topiramate
Publikationsdatum: 01.04.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-36399-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Developmental disabilities after in utero exposure to topiramate

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Olaparib

Alteplase

Dexamethasone

Carbamazepine

Tocilizumab

Other adverse reaction research